Akinboro O, Larkins E, Pai-Scherf LH, Mathieu LN, et al. FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC. Clin Cancer Res 2022;28:2221-2228.
PMID: 35101885